Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Graph machine learning (GML) is receiving growing interest within the pharmaceutical and
biotechnology industries for its ability to model biomolecular structures, the functional …

Recent progress in targeting KRASG12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …

Anticancer uses of non-oncology drugs have occasionally been found, but such discoveries
have been serendipitous. We sought to create a public resource containing the growth …

KRAS GTPases are activated in one-third of cancers, and KRAS (G12C) is one of the most
common activating alterations in lung adenocarcinoma,. KRAS (G12C) inhibitors, are in …

Targeting tumor cell metabolism is an attractive form of therapy, as it may enhance treatment
response in therapy resistant cancers as well as mitigate treatment-related toxicities by …

Motivation Screening bioactive compounds in cancer cell lines receive more attention.
Multidisciplinary drugs or drug combinations have a more effective role in treatments and …

Cancer is a leading cause of death worldwide. Identifying the best treatment using
computational models to personalize drug response prediction holds great promise to …

Multitargeting compounds comprising activity on more than a single biological target have
gained remarkable relevance in drug discovery owing to the complexity of multifactorial …

Large language models (LLMs) have been shown to have significant potential in few-shot
learning across various fields, even with minimal training data. However, their ability to …